Core Viewpoint - The company has received regulatory approval for its Ken-Valve and LuX-ValvePlus products from the New Zealand Medicines and Medical Devices Safety Authority, which will accelerate the global commercialization of its product portfolio [1] Group 1: Product Approval - The Ken-Valve and LuX-ValvePlus systems have recently obtained registration approval in New Zealand [1] - The approval is expected to enhance the company's market presence and facilitate the commercialization of these products [1] Group 2: Market Recognition - The products have gained widespread recognition in the market due to their design advantages and ongoing clinical trials [1] - Continuous promotion of the therapies has contributed to the positive reception of the products [1] Group 3: Strategic Goals - The company aims to expedite the global commercialization process of its product lineup to achieve its long-term strategic objectives [1]

Core Viewpoint - The company has received regulatory approval for its Ken-Valve and LuX-Valve Plus products in New Zealand, which will accelerate the global commercialization of its product portfolio [1] Group 1: Product Approval - Ken-Valve and LuX-Valve Plus have been approved by the New Zealand Medicines and Medical Devices Safety Authority [1] - The approval is expected to enhance the company's market presence and recognition due to the design advantages and ongoing clinical trials [1] Group 2: Commercialization Strategy - The company is actively promoting the commercialization of these two products in New Zealand [1] - The approval aligns with the company's long-term strategic goals for global market expansion [1]

据此前招股书，天星医疗是一家专注于运动医学整体临床解决方案的创新型医疗器械公司。据灼识咨询数据，按2024年销售收入计，天星医疗是中国最大的 国产运动医学公司。 截至最后实际可行日期，天星医疗拥有国内最全面的运动医学产品，主要涵盖植入物、有源设备及相关耗材、手术工具等52款产品，可以提供整体临床运动 医学解决方案。第三类医疗器械20款，5款产品在中国市场上所有品牌中首个获批并应用于临床，10款产品在国产品牌中首个获批并应用于临床。此外，天 星医疗在运动医学及智能康复领域的在研产品超过35个。 于往绩记录期间，依托多元化的产品矩阵，公司在中国市场实现了深度渗透：截至2022年12月31日，公司的产品已经进入医院数量超过1,000家，截至2024 年12月31日已增至3,000余家，其中三级医院超过1,000家。 北京天星医疗股份有限公司(简称：天星医疗)于2025年8月26日所递交的港股招股书满6个月，于2026年2月26日失效，递表时中信证券、建银国际为其联席 保荐人。 | 26/08/2025 | 北京天星醫療股份有限公司 | | --- | --- | | | 09/09/2025 整體協調人公告 - 委 ...

Core Viewpoint - The company has received regulatory approval for its Ken-Valve and LuX-Valve Plus products in New Zealand, which will accelerate its global commercialization efforts [1] Group 1: Product Approval - The Ken-Valve and LuX-Valve Plus have recently obtained registration approval from the New Zealand Medicines and Medical Devices Safety Authority [1] - The approval is expected to enhance the company's market presence and facilitate the commercialization of these products in New Zealand [1] Group 2: Market Recognition - The products have gained widespread recognition in the market due to their design advantages, ongoing clinical trials, and continuous therapy promotion efforts [1] - The successful registration of these two key products aligns with the company's long-term strategic goals [1]

Group 1: Economic Cooperation and Policies - The Chinese government expresses hope for the U.S. to view the implementation of the Phase One trade agreement objectively and rationally, urging against blame-shifting and provocations [1] - The Shanghai government has announced a reduction in housing purchase restrictions, including an increase in the maximum loan amount for first-time homebuyers from 1.6 million to 2.4 million yuan, with potential increases for families with multiple children [1] - The Guangzhou government is supporting financial product diversification to foster investment in technology and long-term projects [1] Group 2: Financial and Economic Forecasts - The International Monetary Fund (IMF) projects the U.S. GDP to grow by 2.6% in 2026, up from a previous forecast of 2.4% [3] - The Hong Kong government forecasts economic growth of 2.5% to 3.5% for the current year, with inflation rates expected at 1.7% and 1.8% respectively [1] - The "Inclusive Finance Prosperity Index" for January 2026 reached 49.60 points, indicating a slight increase, with financing conditions improving due to seasonal demand and policy support [1] Group 3: Company Announcements - Haiguang Information expects Q1 2026 revenue to be between 3.91 billion and 4.22 billion yuan, representing a year-on-year growth of 62.91% to 75.82% [1] - Transsion Holdings anticipates a 53.43% decline in net profit for 2025, down to 2.584 billion yuan [1] - Union Medical's net profit for 2025 is projected to increase by 49.60% to 1.888 billion yuan [1]

(一)股东会召开的时间：2026年2月25日 (二)股东会召开的地点：淄博市高新技术产业开发区泰美路7号新华医疗科技园办公楼三楼会议室 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ●本次会议是否有否决议案：无 一、会议召开和出席情况 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： ■ (四)表决方式是否符合《公司法》及《公司章程》的规定，会议主持情况等。 本次股东会由公司董事会召集，董事长王玉全先生主持，会议采用现场投票与网络投票相结合的方式表 决，符合《公司法》、《公司章程》等法律、法规及规范性文件的规定。 (五)公司董事和董事会秘书的列席情况 1、公司在任董事11人，列席11人； 2、公司总经理巩报贤先生、副总经理兼董事会秘书李财祥先生、副总经理屈靖先生、董事兼财务总监 周娟娟女士、副总经理朱庆国先生、副总经理王加强先生出席了会议。 二、议案审议情况 (一)累积投票议案表决情况 1、关于换选公司董事的议案 ■ (二)涉及重大事项，5%以下股东的表决情况 ■ (三)关于议案表决的有关 ...

中泰证券指出，把握医药结构性行情，持续关注医药/医疗AI+，基本面有积极变化的轻筹码标的。本周 沪深300上涨0.36%，医药生物下滑0.81%，处于31个一级子行业第21位，本周医疗服务上涨0.22%，化 学制药、生物制品、医疗器械、中药、医药商业分别下跌0.54%、0.89%、1.07%、1.75%、2.68%。本周 医药行情分明显，AI医疗、前期回调明显的小核酸相关标的、基本面有边际变化且机构筹码较轻的部 分个股表现亮眼。我们认为医药作为兼具科技和消费属性的板块，在市场行情的轮动中将持续呈现结构 性行情，关于科技属性，创新药板块已经历了过去一年来的急涨后回调，相比2025年年初的位置，普遍 标的估值合理，因此建议关注所在细分行业（优选小核酸、体内CAR、ADC、二代IO、protac等）及公 司本身基本面有边际变化且持续性有望兑现的标的，医药/医疗AI+则是近期热度持续高涨的新方向，除 关注赛道龙头外，建议关注主营业务非医药/医疗AI+相关，但积极拥抱相关技术并预期能够中短期内兑 现估值弹性的标的；消费方面，目前2025年业绩预告基本发布完成，基本体现在当下股价，建议关注中 药、医美等消费医疗板块中积极 ...

智通财经APP获悉，中泰证券发布研报称，医药作为兼具科技和消费属性的板块，在市场行情的轮动中 将持续呈现结构性行情，关于科技属性，创新药板块已经历了过去一年来的急涨后回调，相比2025年年 初的位置，普遍标的估值合理，因此建议关注所在细分行业(优选小核酸、体内CAR、ADC、二代IO、 protac等)及公司本身基本面有边际变化且持续性有望兑现的标的，医药/医疗AI+则是近期热度持续高涨 的新方向，除关注赛道龙头外，建议关注主营业务非医药/医疗AI+相关，但积极拥抱相关技术并预期能 够中短期内兑现估值弹性的标的。 中泰证券主要观点如下： 把握医药结构性行情，持续关注医药/医疗AI+，基本面有积极变化的轻筹码标的。 本周沪深300上涨0.36%，医药生物下滑0.81%，处于31个一级子行业第21位，本周医疗服务上涨 0.22%，化学制药、生物制品、医疗器械、中药、医药商业分别下跌0.54%、0.89%、1.07%、1.75%、 2.68%。本周医药行情分明显，AI医疗、前期回调明显的小核酸相关标的、基本面有边际变化且机构筹 码较轻的部分个股表现亮眼。 该行认为医药作为兼具科技和消费属性的板块，在市场行情的轮动中 ...

Group 1: Real Estate Policy Changes - Shanghai has implemented a new notification to optimize and adjust the city's real estate policies, effective from February 26, which includes reducing housing purchase restrictions for non-local residents and allowing them to buy additional properties in certain areas [1][5] - The notification also optimizes housing provident fund policies [1] Group 2: Company Earnings Reports - Sainuo Medical reported a total revenue of 525 million yuan for 2025, a year-on-year increase of 14.53%, and a net profit of 47.29 million yuan, showing a significant growth of 3057.05% [5][6] - Haiguang Information achieved a revenue of 14.376 billion yuan in 2025, up 56.91%, with a net profit of 2.542 billion yuan, increasing by 31.66% [5] - Nanya New Materials reported a net profit of 241 million yuan for 2025, a growth of 378.65% [6] - Aibo Medical plans to acquire 68.31% of Demai Medical for 683 million yuan, aiming to enhance its position in the health sector [6][7] Group 3: Market Developments - The Hong Kong government has announced plans to revise listing requirements for companies with dual-class shares and to facilitate the listing process for biotech firms [2][3] - The sales of home appliances and digital products during the recent Spring Festival reached 5.106 million units, a 21.7% increase compared to the previous year, with offline sales accounting for 73.3% of total sales [4] Group 4: Corporate Actions - Wens Foodstuff Group plans to repurchase shares worth between 800 million to 1.2 billion yuan at a maximum price of 24 yuan per share [8] - ST Xinhua Jin has received a notice from the China Securities Regulatory Commission regarding an investigation for information disclosure violations, leading to a temporary suspension of its stock [9] - Gree Electric Appliances' largest shareholder plans to reduce its stake by up to 2% through block trading to repay bank loans, without affecting control of the company [10] Group 5: Industry Insights - A report from CITIC Securities indicates that the demand for AI data centers (AIDC) is expected to grow rapidly, with a compound annual growth rate of approximately 55% from 2025 to 2028, leading to significant opportunities in the power supply sector [10]

中科院院士王建安：让脑机接口技术从实验室走向病房 中新社杭州2月25日电 (张煜欢)"当前，脑机接口正处于技术爆发期，包括中国在内的多个国家和地区在 加速布局，抢占全球脑科学战略高地。脑机接口的成果转化和广泛应用，离不开相关医疗器械产业的高 质量发展，各方都应前瞻布局、系统突破。" 全国政协委员、中国科学院院士、浙江大学医学院附属第二医院(下称浙大二院)院长王建安近期受访时 如是说。 高位截瘫的患者，通过"意念"控制，能喝水进食、写下汉字；下肢瘫痪的患者，能够重新站立、行 走……听起来像是科幻电影场景，正随着脑机接口技术发展一步步照进现实。 王建安深知，这项"读懂大脑"的前沿技术，正处于从实验室走向病房的爆发前夜，机遇与挑战并存。 赛迪顾问去年发布的"中国脑机接口产业发展现状及趋势"显示，2024年中国市场规模为32亿元(人民 币，下同)，预计2027年将达55.8亿元。 一系列临床突破接连落地。王建安介绍，以其所在的浙大二院为例，2012年就联合浙江大学推进脑机接 口植入技术，并于两年后实现意念控制机械手完成高难度猜拳动作。2025年初，该院为一名截瘫患者施 行闭环脊髓神经接口植入术，术后患者实现拄拐自主行 ...